cov khoom siv

Oleoylethanolamide (OEA) hmoov

Oleoylethanolamine (OEA) yog lub cev zom zaws tshuaj ethanolamide lipid thiab nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) agonist. Nws ua nyob rau hauv txoj hnyuv me thiab txwv tsis pub kom muaj zaub mov noj raws kev ua haujlwm ntawm PPAR-α ua kom muaj zog. OEA tseem ua kom GPR119, yog ib qho lipid lipid nrog hypophagic thiab los tiv thaiv kev rog.

Chaw Tsim Tshuaj:  Batch Ntau Lawm
pob: 1KG / hnab, 25KG / nruas
Wisepowder muaj peev xwm tsim tau thiab muab khoom ntau. Txhua qhov kev tsim khoom raws li cGMP thiab kev tswj hwm nruj, tag nrho cov ntaub ntawv xeem thiab cov qauv muaj.

Oleoylethanolamide (111-58-0) video

 

 

Oleoylethanolamide (111-58-0) Cov Ntaub Ntawv Qhia Txog Qib

lub npe Oleoylethanolamide
CAS 111-58-0
purity 85%, 98%
Tshuaj lub npe N-Oleoylethanolamide
Synonyms N-Oleoylethanolamine, N- (Hydroxyethyl) oleamide, N- (cis-9-Octadecenoyl) ethanolamine, OEA
molecular Formula C20H39NO2
molecular Nyhav 325.53
Melting Point 59–60 ° C (138–140 ° F; 332–333 K)
InChI Qhov Tseem Ceeb BOWVQLFMWHZBEF-KTKRTIGZSA-N
daim ntawv khoom
tsos Dawb khoom
Ib Sim Neej /
solubility H2O: <0.1 mg / mL (insoluble); DMSO: 20.83 mg / mL (63.99 mM; Xav tau ultrasonic
cia mob -20 ° C
Daim ntawv thov N-Oleoylethanolamine tau siv los kawm nws cov teebmeem ntawm glucagon zoo li peptide (GLP) -1RA-mediated anorectic signaling thiab poob phaus.
Kuaj Cov Ntaub Ntawv Qhov

 

Oleoylethanolamide (111-58-0) Cov Lus Qhia dav dav

OEA yog cov tshuaj sib xyaw ua ke ntau heev ntawm cov txiv ntseej roj. RiduZone tau tsim los siv cov txiaj ntsig ntawm cov zaub mov nruab nrab thiab pab txhawb kev poob phaus.

RiduZone (OEA Capsule) tau txais los ntawm FDA los ua kev noj haus tshiab.

OEA yog lub ntuj tswj kev ua kom qab los noj mov, hnyav thiab cov roj (cholesterol).

Oleoylethanolamide (OEA) yog cov tshuaj lom neeg lub cev (metabolite) uas tsim los hauv kev muaj me me hauv koj txoj hnyuv. OEA pab tswj cov kev tshaib kev nqhis, qhov hnyav, lub cev rog thiab cov roj cholesterol los ntawm qhov khi nrog lub receptor hu ua PPAR-Alpha (Peroxisome proliferator-activated receptor alpha). Hauv cov ntsiab lus, OEA nce cov metabolism hauv lub cev rog thiab qhia koj lub hlwb tias koj muaj tag nrho thiab nws yog lub sijhawm txwv tsis pub noj mov. OEA kuj tseem paub kom nce kev siv dag zog tsis muaj feem cuam tshuam txog kev siv nyiaj calories.

 

Oleoylethanolamide (111-58-0) Keeb kwm

Oleoylethanolamide lub zog kev ua haujlwm tau tshawb pom ntxov txij li 50 xyoo dhau los. Ua ntej xyoo 2001, tsis tau muaj kev tshawb fawb ntau ntau txog OEA. Txawm li cas los xij, xyoo ntawd, cov kws tshawb nrhiav Spanish tau rhuav tshem cov lipid thiab kawm seb nws ua li cas, qhov twg nws siv thiab nws ua li cas. Lawv tau sim cov OEA cuam tshuam rau lub paj hlwb (ntawm nas) los ntawm kev txhaj nws ncaj qha rau cov leeg hlwb. Lawv pom tias tsis muaj dab tsi cuam tshuam rau kev noj mov thiab paub tseeb tias OEA tsis ua haujlwm hauv lub hlwb, tab sis, theej nws ua rau muaj cov cim cais uas cuam tshuam rau kev tshaib plab thiab kev noj mov tus cwj pwm.

 

Oleoylethanolamide (111-58-0) Kev Ntsuas Ntawm Kev Ua

Txhawm rau muab tso rau nws yooj yim, oleoylethanolamide ua haujlwm ua rau tus neeg tshaib plab. OEA tuaj yeem tswj hwm koj cov zaub mov noj kom tsawg los ntawm kev qhia rau lub hlwb hais tias lub cev tau puv lawm, thiab tsis tas yuav muaj zaub mov ntxiv lawm. Koj noj tsawg dua txhua hnub, thiab koj lub cev yuav tsis rog dhau sijhawm hauv lub sijhawm ntev.

Kev tiv thaiv kev rog rog ntawm oleoylethanolamide (OEA) yog pom tias muaj nyob hauv daim duab. OEA synthesized thiab sib sau nyob rau hauv qhov sib thooj ntawm txoj hnyuv me me los ntawm cov khoom noj muaj txiaj ntsig oleic acid, xws li txiv roj roj. Noj cov zaub mov muaj roj tuaj yeem tiv thaiv OEA ntau lawm hauv cov hnyuv. OEA txo cov khoom noj kom tsawg los ntawm kev ua kom lub ntsej muag homeostatic oxytocin thiab histamine lub hlwb ncig ua ke nrog rau cov kab mob dopamine. Muaj cov ntaub ntawv pov thawj hais tias OEA kuj tseem tuaj yeem pom muaj kev tiv thaiv hedonic cannabinoid receptor 1 (CB1R) cov paib, qhov kev ua kom zoo uas cuam tshuam nrog kev nce ntxiv ntawm cov khoom noj. OEA txo cov lipid thauj mus rau hauv adipocytes kom txo cov rog rog. Ntxiv elucidation ntawm kev cuam tshuam ntawm OEA rau kev noj zaub mov noj thiab lipid metabolism yuav pab hauv kev txiav txim siab ntawm lub cev kev ua haujlwm uas tuaj yeem raug tsom kom tsim kho kev rog rog kom ua haujlwm tau zoo dua.

OEA ua haujlwm kom ua kom ib yam dab tsi hu ua PPAR thiab ua ke txhawb kev ua kom rog thiab ua kom cov rog rog tsawg dua. Thaum koj noj, OEA qib nce ntxiv thiab koj lub qab los noj mov tsawg zuj zus thaum lub ntsaws siab uas txuas nrog koj lub hlwb qhia nws tias koj puv lawm. PPAR-α yog ib pab pawg ntawm ligand-activated nuclear receptor uas koom nrog rau cov gene qhia ntawm lipid metabolism thiab energyhomeostasis pathways.

OEA qhia tau tag nrho cov kev txhais lub ntsiab ntawm qhov muaj txiaj ntsig:

(1) nws inhibits kev pub mis los ntawm kev ncua lub caij nyoog mus rau pluas noj tom ntej;

(2) Nws cov synthesis yog tswj los ntawm kev muaj khoom noj khoom haus zoo thiab

(3) Nws cov theem muaj kev cuam tshuam circadian hloov pauv.

 

Oleoylethanolamide (111-58-0) Daim Ntawv Thov

N-Oleoylethanolamide yog ib qho agonist ntawm peroxisome proliferator-activated receptor-α (PPAR-α). N-Oleoylethanolamide tsim cov kab mob hauv plab uas ua rau lub hauv paus dopamine kev ua haujlwm tsim kom muaj kev sib txuas ntawm caloric-homeostatic thiab hedonic-homeostatic controllers. Oleoylethanolamide tau raug cuam tshuam raws li cov txheej txheem molecular cuam tshuam nrog kev ua tiav ntawm plab hnyuv. N-Oleoylethanolamide yog xaiv GPR55 agonist.

 

Oleoylethanolamide (111-58-0) Kev tshawb fawb ntau ntxiv

Hauv ib txoj kev tshawb nrhiav, tsib caug (n = 50) tib neeg cov ncauj lus uas xav kom poob ceeb thawj tau qhia kom noj OEA 2-3 zaug / hnub, 15-30 feeb ua ntej noj mov rau 4-12 lub lis piam. Cov ntsiab lus suav nrog cov uas tsis tau siv cov khoom hnyav poob ua ntej, cov neeg uas tau ntsib cov kev tsis zoo nrog lwm cov khoom poob phaus, cov uas lawv poob phaus rau lwm cov neeg yuag poob xws li phentermine, cov uas sim siv lub neej hloov pauv (feem tswj thiab ib ce muaj zog tsis tu ncua) ), thiab cov nquag saib xyuas raug mob rau kev kho mob suav nrog kev ua kom tsis muaj qabzib tsis txaus, dyslipidemia, kub siab thiab mob plawv.

Hauv qhov kev tshawb nrhiav thib ob, 4 yam nrog qhov ntsuas qhov hnyav ntawm 229, 242, 375 thiab 193 lbs feem, tau qhia kom noj Oleoylethanolamide capsules (ib qho tshuaj ntsiav muaj 200mg 90% OEA). Cov kws kawm tau noj 4 tsiav tshuaj (1 tshuaj ntsiav 15-30 feeb ua ntej noj mov thiab lawv yuav tsum noj ib qho tshuaj ntsiav ntxiv ua ntej lawv yuav noj mov ntau tshaj plaws hauv hnub) txhua hnub hauv 28 hnub. Cov kev kawm yav dhau los tau ua yav dhau los tau ua dhau los ntawm kev muab cov ceg ntoo tso rau. Cov neeg kawm raug qhia kom tsis hloov pauv rau lawv lub cev kev tawm dag zog thiab tawm dag zog.

 

Oleoylethanolamide (111-58-0) Kev siv

  • Sasso, O., li. al.: Mob, 154, 350 (2013); Begg, DP, Woods, SC: Cell Met., 18, 459 (2013); Chem. thiab Eng. Xov Xwm p.7, Lub Ib Hlis 8 (2017)
  • Gaetani S, Oveisi F, Piomelli D (2003). "Kev hloov pauv ntawm cov qauv noj mov hauv cov nas los ntawm cov anorexic lipid mediator oleoylethanolamine". Neuropsychopharmacology. 28 (7): 1311– doi: 10.1038 / sj.npp.1300166. PMID 12700681.
  • Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, Piomelli D (2005). "Kev tswj kev noj haus los ntawm oleoylethanolamine". Ntawm tes. Mol. Lub Neej Sci. 62 (6): 708– doi: 10.1007 / s00018-004-4494-0. PMID 15770421.
  • Oleoylethanolamide (OEA): Cov Tshuaj Pab Kom Qhov Rog Kom Txog Ntawm Lub Cev Uas Pab Ceeb Toom

 

Cov Lus Trending